Naples-headquartered Enveric Biosciences has received a second Notice of Allowance from the U.S. Patent and Trademark Office for its EVM401 Series compounds, expanding its intellectual property in the treatment of mental health disorders. The patent covers a group of novel, nonhallucinogenic molecules designed to promote neuroplasticity — offering a potential new path for treating PTSD and related conditions. These new compounds are structurally distinct from methylone, a synthetic cathinone recently linked to positive trial results but without patent exclusivity. Enveric aims to provide safe, repeat-dose outpatient treatments using its proprietary Psybrary™ drug development platform. The compounds will undergo further preclinical testing.